reports
United Fire Group, Inc. Reports on Annual Meeting of Shareholders
United Fire Group, Inc. Reports on Annual Meeting of Shareholders Director Elections to the Board of Directors Announced Director Elections to the Board of Directors CEDAR RAPIDS, Iowa, May 16, 2024 (GLOBE NEWSWIRE) -- United Fire Group, Inc. (Nasdaq: UFCS) (the "Company" or "UFG") announced today that its shareholders elected four Class C Directors to our 11-member board of directors at the 2024 Annual Meeting of Shareholders held on May 15, 2024. The following individuals were each elected as Class C Directors to serve three-year terms expiring in 2027. Mark A. Green, Operating Part...
Evolus Inc: 5 directors
Five Directors at Evolus Inc sold after exercising options/sold 60,276 shares at between 12.645USD and 12.929USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...
United Fire Group, Inc. Declares a Common Stock Quarterly Cash Dividen...
United Fire Group, Inc. Declares a Common Stock Quarterly Cash Dividend of $0.16 per Share CEDAR RAPIDS, IOWA , May 15, 2024 (GLOBE NEWSWIRE) -- Today, the Board of Directors of United Fire Group, Inc. (Nasdaq: UFCS) ("UFG") declared a common stock quarterly cash dividend of $0.16 per share. This dividend will be payable June 14, 2024 to shareholders of record as of May 31, 2024. UFG has a long history of paying quarterly dividends, with the quarterly cash dividend declared today marking the 225th consecutive quarterly dividend paid, dating back to March 1968. About UFG Founded i...
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in M...
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis —With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval with clinical outcomes to support the potential for confirmatory or full approval— SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clin...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company’s common stock to four new employees (the “Inducement Gra...
89bio Reports First Quarter 2024 Financial Results and Provides Corpor...
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update –Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH patients with compensated cirrhosis (F4)– –Granted Priority Medicines (PRIME) status from the European Medicines Agency (EMA) for pegozafermin in the treatment of MASH with fibrosis and compensated cirrhosis– –Data from the 48-Week Extension Phase of the ENLIVEN Phase 2b Trial to ...
- Matt Quigley
- Tom Nikic
- Wedbush Research
TXRH TEXAS ROADHOUSE INC.
RNG RINGCENTRAL INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
IMAX IMAX CORPORATION
GLPI GAMING AND LEISURE PROPERTIES INC.
DIN DINE BRANDS GLOBAL INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
BJRI BJ'S RESTAURANTS INC.
DRI DARDEN RESTAURANTS INC.
OKTA OKTA INC. CLASS A
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
IGMS IGM BIOSCIENCES
DDOG DATADOG INC CLASS A
RVMD REVOLUTION MEDICINES
ABNB AIRBNB INC. CLASS A
PHVS PHARVARIS NV
RMBL RUMBLEON INC
APP APPLOVIN CORP
BIRD ALLBIRDS INC
JANX JANUX THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
CART MAPLEBEAR INC.
89bio to Participate in the BofA Securities 2024 Health Care Conferenc...
89bio to Participate in the BofA Securities 2024 Health Care Conference SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the BofA Securites 2024 Health Care Conference on Wednesday, May 15, 2024 at 2:20 PM PDT and participate in one-on-one investor meetings. The webcast of the presentation will be accessible and in the investor s...
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
Douglas Emmett Releases First Quarter 2024 Earnings Results
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Douglas Emmett, Inc. (NYSE: DEI), a real estate investment trust (REIT), has released its First Quarter 2024 Earnings Results and Operating Information package by posting it to the investor relations section of its website at . As previously announced, Jordan Kaplan, CEO, Peter Seymour, CFO, Kevin Crummy, CIO, and Stuart McElhinney, Vice President Investor Relations will host a live conference call to discuss Douglas Emmett’s financial results at 2:00 pm Eastern Time (11:00 am Pacific Time) on Wednesday, May 8, 2024. Interested parties can listen to th...
United Fire Group, Inc. Reports First Quarter 2024 Results
United Fire Group, Inc. Reports First Quarter 2024 Results First Quarter Net Income of $0.52 per Diluted Share and Adjusted Operating Income of $0.56 per Diluted Share First quarter 2024 highlights: Net income of $13.5 million increased compared to the first quarter of 2023, driven by underwriting income and higher investment income.Net premiums written(1) of $321.3 million increased 17.6% compared to the first quarter of 2023.GAAP combined ratio of 98.9%, including a loss ratio of 64.0% and underwriting expense ratio of 34.9%, improved 4.5 points compared to the first quarter of ...
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity...
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event of pegozafermin’s opportunity in advanced metabolic dysfunction-associated ste...
Pitney Bowes Declares Common Stock Dividend
STAMFORD, Conn.--(BUSINESS WIRE)-- Pitney Bowes Inc. (NYSE:PBI), a global shipping and mailing company that provides technology, logistics, and financial services, today announced that its Board of Directors has declared a quarterly cash dividend on the company’s common stock of $0.05 per share. The dividend will be paid on June 7, 2024 to stockholders of record on May 23, 2024. About Pitney Bowes Pitney Bowes (NYSE:PBI) is a global shipping and mailing company that provides technology, logistics, and financial services to more than 90 percent of the Fortune 500. Small business, retail, en...
Pitney Bowes Announces First Quarter 2024 Financial Results
STAMFORD, Conn.--(BUSINESS WIRE)-- Pitney Bowes (NYSE: PBI) (“Pitney Bowes” or the “Company”), a global shipping and mailing company that provides technology, logistics, and financial services, today announced its financial results for the first quarter 2024. Jason Dies, Interim Chief Executive Officer, commented: “We came out of the gate strong with first quarter results that reflect enterprise-wide changes in our operating intensity and efficiency efforts. Net income improved $5 million over prior year. Adjusted EBIT grew by more than $23 million on relatively flat revenue. This includes...
- Brian Violino
- Jay McCanless
Landsea Homes Reports First Quarter 2024 Results
Landsea Homes Reports First Quarter 2024 Results First Quarter 2024 Highlights First quarter net new home orders of 612, a 23% year-over-year increaseTotal revenue of $294.0 million, driven by 505 home closings at an average price of $579,000Adjusted EBITDA of $17.0 millionBook value per share of $17.92Repurchased approximately 534,000 shares of common stock for $6.4 million DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded homebuilder, reported financial results for the first quarter ended...
- Wedbush Research
LOGN LOGITECH INTERNATIONAL S.A.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RWT REDWOOD TRUST INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PCRX PACIRA BIOSCIENCES INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FATE FATE THERAPEUTICS INC
EXLS EXLSERVICE HOLDINGS INC.
EAT BRINKER INTERNATIONAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
SWKS SKYWORKS SOLUTIONS INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
HPE HEWLETT PACKARD ENTERPRISE CO.
TWTR TWITTER INC.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
BCEL ATRECA
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
AQST INC.
IDYA AQUESTIVE THERAPEUTICS
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
CRSR ADICET BIO INC
ITOS CORSAIR GAMING
ZNTL ITEOS THERAPEUTICS
PRAX ZENTALIS PHARMACEUTICALS
FUBO PRAXIS PRECISION MEDICINES
TVTX FUBOTV
LSEA TRAVERE THERAPEUTICS INC
VRDN LANDSEA HOMES CORP (A)
DAWN VIRIDIAN THERAPEUTICS INC
ELEV DAY ONE BIOPHARMACEUTICALS INC
OMGA ELEVATION ONCOLOGY
LBPH OMEGA THERAPEUTICS
THRX LONGBOARD PHARMACEUTICALS
MRVL THESEUS PHARMACEUTICALS
STX INC.
DSGN MARVELL TECHNOLOGY INC
ATXS SEAGATE TECHNOLOGY HLDGS PLC
AVTE DESIGN THERAPEUTICS INC
GFS ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX GLOBALFOUNDRIES INC
FUSN RALLYBIO CORP
VIGL KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- Brian Violino
- Jay McCanless
American Assets Trust, Inc. Reports First Quarter 2024 Financial Resul...
American Assets Trust, Inc. Reports First Quarter 2024 Financial Results Net income available to common stockholders of $19.3 million for the first quarter, or $0.32 per diluted share. Funds from Operations ("FFO") per diluted share increased 8% year-over-year for the first quarter to $0.71 per diluted share. Increased 2024 FFO per diluted share guidance to a range of $2.24 to $2.34 with a midpoint of $2.29, a 1% increase over prior guidance. SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.